Encontrados 4 documentos, a visualizar página 1 de 1
Prostate cancer progression
Sousa, RD; Zagalo, Daniela Mariana; Gouveia, Miguel; Gomes, Luís Antunes; Santos Dias, José; Mansinho, André; Santos, Susana; Mariano, JoséAIMS/BACKGROUND: Prostate cancer is the most common malignancy in men and a leading cause of cancer-related death. Progression from non-metastatic castration-resistant prostate cancer (nmCRPC) to metastatic CRPC (mCRPC) significantly worsens health-related quality of life (HRQoL), increases mortality, and raises healthcare costs. This study assessed the impact of avoiding or delaying progression to mCRPC on HRQ...
Identification of biomarkers predictive of metastasis development in early-stag...
Peixoto, Carolina; Lopes, Marta B.; Martins, Marta; Casimiro, Sandra; Sobral, Daniel; Grosso, Ana Rita; Abreu, Catarina; Macedo, DanielaPublisher Copyright: © 2023, The Author(s).; Colorectal cancer (CRC) is the third most common cancer and the second most deathly worldwide. It is a very heterogeneous disease that can develop via distinct pathways where metastasis is the primary cause of death. Therefore, it is crucial to understand the molecular mechanisms underlying metastasis. RNA-sequencing is an essential tool used for studying the transcr...
Genetic and microenvironmental intra-tumor heterogeneity impacts colorectal can...
Sobral, Daniel; Martins, Marta; Kaplan, Shannon; Golkaram, Mahdi; Salmans, Michael; Khan, Nafeesa; Vijayaraghavan, Raakhee; Casimiro, SandraWe thank João Neto and remaining Computational Multi-Omics Lab members at UCIBIO for their helpful comments and suggestions. © 2022. The Author(s).; Colorectal cancer (CRC) is a highly diverse disease, where different genomic instability pathways shape genetic clonal diversity and tumor microenvironment. Although intra-tumor heterogeneity has been characterized in primary tumors, its origin and consequences in ...
Predictive and Therapeutic Implications of a Novel PLCγ1/SHP2-Driven Mechanism ...
Cruz-Duarte, Raquel; de Almeida, Cátia Rebelo; Negrão, Magda; Fernandes, Afonso; Borralho, Paula; Sobral, Daniel; Gallego-Paez, Lina M.; Machado, DanielP. Borralho reports grants from Roche and Novartis, as well as personal fees from Bayer and AstraZeneca outside the submitted work. D. Machado reports personal fees from Amgen and Merck outside the submitted work. H. Mansinho reports grants from AstraZeneca; nonfinancial support from AstraZeneca; and personal fees from Roche, Pfizer, Pierre Fabre, Incyte, BMS, Novartis, Amgen, Servier, Merck Serono, and Grunent...